CV Sciences trims losses, boosts margins but faces shrinking sales and tight liquidity

Quick read - what's happening inside CV Sciences, Inc. (OTCBB: CVSI)

CV Sciences reported results for the quarter and six months ended June 30, 2025 showing a business that is cutting costs and improving gross margins but still shrinking top-line volume and running with thin liquidity. The company continues integration of two recent acquisitions (Cultured Foods and Elevated Softgels), has new lease commitments, and used secured note financing in early 2025 to shore up cash.

Key facts and headline statistics (as reported)
* Product sales Q2 2025: $3,620,000 (Q2 2024: $3,954,000; change -8.4%).
* Gross profit Q2 2025: $1,844,000; gross margin Q2 2025: 50.9% (Q2 2024 margin 47.0%).
* Operating loss Q2 2025: $(131,000) (Q2 2024: $(583,000)).
* Net loss Q2 2025: $(261,000); six months ended June 30, 2025 net loss: $(370,000) (six months 2024: $(1,212,000)).
* Adjusted EBITDA Q2 2025: $59,000 (six months 2025: $(252,000)).
* Cash at June 30, 2025: $886,000 (beginning of year $454,000).
* Total assets: $7,950,000; total liabilities: $6,147,000; stockholders' equity: $1,803,000.
* Accumulated deficit: $(87,351,000).
* Inventory at June 30, 2025: $4,216,000.
* Debt: note payable, net $1,211,000 (current portion $1,023,000; long-term $208,000).
* February 2025 secured promissory note: original principal $1,600,000 with $400,000 original issuance discount - net proceeds received $1,200,000; note due Aug 12, 2026 with monthly payments and events-of-default that can materially increase balance and trigger interest.

Positive aspects of the income statement and operations
* Gross margin improved materially - Q2 margin rose to 50.9% from 47.0% year-over-year, driven by lower freight, fewer inventory losses and favorable product/channel mix despite lower volume.
* Gross profit remained effectively flat quarter-over-quarter ($1.844M vs $1.860M) while sales declined, indicating cost-of-goods improvements.
* SG&A expense down significantly: Q2 SG&A $1.925M vs $2.415M in prior-year quarter (≈20% reduction) reflecting lower legal fees, reduced marketing/travel and other cost controls.
* Operating loss narrowed sharply (Q2: $(131k) vs $(583k) prior year) and Adjusted EBITDA turned positive in Q2 ($59k), showing near-term operational improvement.
* Cash flow from operations improved: six months to June 30, 2025 generated $206k of operating cash (versus used cash in prior year). Management has implemented strategic cost reductions.

Negative aspects and risks in the income statement / financials
* Sales decline - product sales fell 8.4% in Q2 and 9.2% for the six months; units sold down (7.0% Q2, 9.5% six months) and ASPs declined, signaling demand pressure and competitive headwinds.
* Net loss persists (Q2 $(261k), six months $(370k)), and accumulated deficit remains large at $(87.4M).
* Interest expense rose (amortization of debt discount) and debt structure contains aggressive default remedies (possible 20% or 5% balance increases and up to 18% default interest) - increases financial leverage and default risk.
* Liquidity thin - cash on hand $886k and working capital ≈ $0.2M; significant near-term principal payments remain (remaining 2025 principal $660k; 2026 $853k; total scheduled principal $1.513M). Company states there is substantial doubt about going concern absent additional capital.
* Non-cash and one-time items are significant: stock-based compensation is meaningful (Q2 $132k; six months $250k); benefit from reversal of accrued payroll taxes ($522k) materially improved results this period but is one-time and tied to statute-of-limitations outcomes.
* Integration costs / higher COGS for acquisitions - Elevated Softgels and Cultured Foods increased COGS in periods presented; new leases and facility costs added right-of-use assets and lease liabilities (~$0.5M).
* Revenue concentration and regulatory uncertainty remain (CBD regulatory complexity and state-level bans can reduce addressable market - California emergency order cited as negative).

Operational & strategic notes
* Channel mix Q2 2025: Retail (B2B) 58.4% ($2.114M) / E-commerce (B2C) 41.6% ($1.506M).
* Company continues product launches (34 products since Jan 1, 2023 - ~38.9% of Q2 revenue from new products) and is in-sourcing softgel manufacturing via Elevated Softgels.
* Management is pursuing further cost reductions, may delay drug development spend, and intends to seek additional capital via equity, debt, or lines of credit. Streeterville note repaid in the period (gain on extinguishment $37.5k).

Bottom line - near-term investor takeaways
* Operationally the company is improving margins and cutting SG&A, which drove a much smaller operating loss and positive Q2 Adjusted EBITDA. That's a constructive sign of better cost control and product margin management.
* However, revenues are declining, liquidity is tight, and the balance sheet carries significant accumulated losses and near-term debt obligations. The company explicitly discloses substantial doubt about its ability to continue as a going concern without additional capital.
* Monitor: cash runway and capital raises; monthly note repayments and covenant/default risk; whether margin improvements sustain as sales stabilize; progress integrating acquisitions and whether they move from cost pressure to revenue contributors; regulatory developments affecting CBD sales (state and federal).

Source: CV Sciences, Inc. Form 10‑Q for quarter ended June 30, 2025 (financials and notes quoted as reported).